From our point of view, HDAC2 may exacerbate immunosuppression by upregulating tumor PD-L1 expression, suggesting that HDAC2 is a promising therapeutic target to control tumor progression, and the development of anticancer drugs specific for HDAC2 may inhibit tumor growth and immune escape of cancers. This evidence concerns the gene HDAC2 and cancer.